Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

actinium Ac 225-DOTA-h11B6 JNJ-69086420

A radioimmunoconjugate containing h11B6, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets human kallikrein-2 (hK2), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-DOTA-h11B6 JNJ-69086420, the monoclonal antibody moiety of JNJ-69086420 targets and binds to hK2, thereby delivering a cytotoxic dose of alpha radiation to hK2-expressing tumor cells. hK2 is overexpressed on a variety of cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[225Ac]-DOTA-h11B6
225Ac-h11B6 JNJ-69086420
actinium-225-labeled anti-kallikrein-2 h11B6 JNJ-69086420
actinium-225-labeled h11B6 JNJ-69086420
Code name:JNJ 69086420
JNJ-69086420
JNJ69086420
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search